Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
INTerpath-13
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- NCT07221474 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on INTerpath-13 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTerpath-13 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Squamous Non-small Cell Lung Cancer
- Interventions
- Intismeran Autogene; Pembrolizumab; Carboplatin; Paclitaxel; Nab-paclitaxel; Placebo
- Arms
- Intismeran Autogene + Pembrolizumab + Chemo · Experimental
- Placebo + Pembrolizumab + Chemo · Experimental
- Enrollment
- 180 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Dec 12, 2025
- Primary completion
- Jul 2, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07221474 · updated Oct 1, 2026